FDA Approves Foundayo: The GLP-1 Pill You Take With Food (April 2026)
Eli Lilly's oral weight loss pill got the fastest FDA approval since 2002 on April 1, 2026. Here's how Foundayo compares to oral Wegovy at $149/month.
Foundayo received FDA approval as the first oral GLP-1 medication for chronic weight management. The approval — announced in April 2026 — is a structural change in how GLP-1 therapy can be delivered.
Key takeaways
- Foundayo is taken once daily with food, no fasting window required
- FDA-approved for chronic weight management in adults with BMI 30+ or 27+ with comorbidity
- Trial data showed meaningful weight loss (9–11% at 12 months)
- Lower than injectable tirzepatide but with significantly better adherence
What FDA approval changes
It clears the way for insurance coverage, employer plan inclusion, and integration into the standard primary-care prescribing flow. The pathway from a primary care visit to an oral GLP-1 prescription is now no different from any other chronic-disease medication.
Compounded oral semaglutide formulations exist but are not equivalent — the Foundayo approval is for a specific, manufacturer-controlled formulation tested in registered trials.
When to consider it
If you've delayed starting GLP-1 therapy because of the injection requirement, this is a reasonable starting point. If you need maximum weight loss as quickly as possible, an injectable like tirzepatide will likely outperform.
Talk to your provider about realistic expectations. Adherence — not raw molecule strength — is usually what determines outcomes.